UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 29.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 115,782 shares of the company's stock after acquiring an additional 26,286 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.15% of Viridian Therapeutics worth $2,220,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in VRDN. Foresite Capital Management VI LLC bought a new stake in Viridian Therapeutics during the fourth quarter valued at $38,000. AlphaQuest LLC boosted its stake in Viridian Therapeutics by 119.0% during the fourth quarter. AlphaQuest LLC now owns 2,795 shares of the company's stock valued at $54,000 after buying an additional 1,519 shares during the period. Summit Investment Advisors Inc. boosted its stake in Viridian Therapeutics by 24.7% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company's stock valued at $147,000 after buying an additional 1,516 shares during the period. Quantbot Technologies LP bought a new stake in Viridian Therapeutics during the fourth quarter valued at $164,000. Finally, KLP Kapitalforvaltning AS bought a new stake in Viridian Therapeutics during the fourth quarter valued at $219,000.

Viridian Therapeutics Trading Up 3.8%

VRDN traded up $0.56 during midday trading on Tuesday, reaching $15.42. 665,185 shares of the company's stock traded hands, compared to its average volume of 1,181,474. The firm has a fifty day moving average of $13.15 and a two-hundred day moving average of $16.17. The stock has a market capitalization of $1.26 billion, a price-to-earnings ratio of -3.58 and a beta of 0.41. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55. Viridian Therapeutics, Inc. has a 52 week low of $9.90 and a 52 week high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($0.87) EPS for the quarter, beating analysts' consensus estimates of ($0.95) by $0.08. The business had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.16 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The business's revenue was up .0% compared to the same quarter last year. On average, equities analysts anticipate that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on VRDN. The Goldman Sachs Group cut their price objective on Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. HC Wainwright reiterated a "buy" rating and issued a $34.00 price objective on shares of Viridian Therapeutics in a report on Wednesday, April 23rd. JMP Securities cut their price objective on Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating for the company in a report on Wednesday, May 7th. Needham & Company LLC reiterated a "buy" rating and issued a $36.00 price objective on shares of Viridian Therapeutics in a report on Tuesday, May 20th. Finally, Royal Bank of Canada cut their price objective on Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $36.70.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.